TY - JOUR
T1 - Neurological Deficits in Stroke Patients that May Impede the Capacity to Provide Informed Consent for Endovascular Treatment Trials
AU - Janssen, Paula M.
AU - Chalos, Vicky
AU - van den Berg, Sophie A.
AU - Kompanje, Erwin J. O.
AU - Nederkoorn, Paul J.
AU - van der Worp, Bart H.
AU - van Zwam, Wim H.
AU - Dippel, Diederik W. J.
AU - MR CLEAN Registry Investigators
N1 - Funding Information:
P.J., V.C., S.vd.B., and E.K. report no disclosures. P.N. reports funding from the Dutch Heart Foundation/ CardioVasculair Onderzoek Nederland, paid to institution. UMC Utrecht received grants from the Dutch Heart Foundation and compensation from Boehringer Ingelheim for consultations by HBvdW. W.vZ. reports compensation from Stryker®, Cerenovus® for consultations and funding from the Dutch Heart Foundation, Dutch Brain Foundation and unrestricted grants from AngioCare B.V., Medtronic/Covidien/EV3®, MEDAC GmBh/LAMEPRO, Penumbra Inc., Stryker®, and Top Medical/Concentric for execution of randomized trials, all paid to institution. D.D. reports compensation from Stryker®, Bracco Imaging® for consultations and funding from the Dutch Heart Foundation, Dutch Brain Foundation and unrestricted grants from AngioCare B.V., Medtronic/Covidien/EV3®, MEDAC GmBh/LAMEPRO, Penumbra Inc., Stryker®, and Top Medical/Concentric for execution of randomized trials, all paid to institution.
Funding Information:
P.J., V.C., S.vd.B., and E.K. report no disclosures. P.N. reports funding from the Dutch Heart Foundation/ CardioVasculair Onderzoek Nederland, paid to institution. UMC Utrecht received grants from the Dutch Heart Foundation and compensation from Boehringer Ingelheim for consultations by HBvdW. W.vZ. reports compensation from Stryker®, Cerenovus® for consultations and funding from the Dutch Heart Foundation, Dutch Brain Foundation and unrestricted grants from AngioCare B.V., Medtronic/Covidien/EV3®, MEDAC GmBh/LAMEPRO, Penumbra Inc., Stryker®, and Top Medical/Concentric for execution of randomized trials, all paid to institution. D.D. reports compensation from Stryker®, Bracco Imaging® for consultations and funding from the Dutch Heart Foundation, Dutch Brain Foundation and unrestricted grants from AngioCare B.V., Medtronic/Covidien/EV3®, MEDAC GmBh/LAMEPRO, Penumbra Inc., Stryker®, and Top Medical/Concentric for execution of randomized trials, all paid to institution.
Funding Information:
Funding: The MR CLEAN Registry was partly funded by TWIN (Toegepast Wetenschappelijk Instituut voor Neuromodulatie) Foundation, Erasmus MC University Medical Center, Maastricht University Medical Center, and Amsterdam UMC, University of Amsterdam.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/12
Y1 - 2019/12
N2 - Background: We assessed the occurrence of neurological deficits that may impede the capacity to provide consent for trial participation in patients with an acute stroke, who are eligible for endovascular treatment (EVT). Methods: We used data from the Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry, a prospective observational cohort study. We included 1526 patients with an anterior large vessel occlusion, undergoing EVT between March 2014 and June 2016. We based our assessment of decision-making capacity for trial participation on neurological symptoms influencing conditions concerning informed consent as stated in the declaration of Helsinki. We formulated a strict and a mild capacity assessment rule, using 2 different cut points in item scores on the National Institutes of Health Stroke Scale (NIHSS). Results: Applying the strict and mild rule, respectively 1469 (96%) and 1220 (80%) patients deemed not capable of decision-making for trial participation on admission, and 1077 (79%) and 825 (60%) patients at 24-48 hours after admission. Highest frequencies of predefined scores suggesting incapacity based on the strict rule were on the NIHSS items "Level of Consciousness Questions" (59%), "Best Gaze" (68%), and "Best Language" (58%). Patients who were considered incapable were older (median 71 versus 66 years, P = .043), had higher NIHSS scores (median 16 versus 8, P <.001), and had more often left hemisphere strokes (55% versus 28%, P <.001) than patients who were presumably capable. Conclusions: In the majority of patients with an anterior circulation stroke who are eligible for EVT, neurological deficits are present that may impede the capacity to provide informed consent for trial participation.
AB - Background: We assessed the occurrence of neurological deficits that may impede the capacity to provide consent for trial participation in patients with an acute stroke, who are eligible for endovascular treatment (EVT). Methods: We used data from the Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry, a prospective observational cohort study. We included 1526 patients with an anterior large vessel occlusion, undergoing EVT between March 2014 and June 2016. We based our assessment of decision-making capacity for trial participation on neurological symptoms influencing conditions concerning informed consent as stated in the declaration of Helsinki. We formulated a strict and a mild capacity assessment rule, using 2 different cut points in item scores on the National Institutes of Health Stroke Scale (NIHSS). Results: Applying the strict and mild rule, respectively 1469 (96%) and 1220 (80%) patients deemed not capable of decision-making for trial participation on admission, and 1077 (79%) and 825 (60%) patients at 24-48 hours after admission. Highest frequencies of predefined scores suggesting incapacity based on the strict rule were on the NIHSS items "Level of Consciousness Questions" (59%), "Best Gaze" (68%), and "Best Language" (58%). Patients who were considered incapable were older (median 71 versus 66 years, P = .043), had higher NIHSS scores (median 16 versus 8, P <.001), and had more often left hemisphere strokes (55% versus 28%, P <.001) than patients who were presumably capable. Conclusions: In the majority of patients with an anterior circulation stroke who are eligible for EVT, neurological deficits are present that may impede the capacity to provide informed consent for trial participation.
KW - Stroke
KW - acute stroke treatment
KW - endovascular treatment
KW - thrombectomy
KW - medical decision making
KW - ACUTE ISCHEMIC-STROKE
KW - MECHANICAL THROMBECTOMY
KW - INTERRATER RELIABILITY
KW - SURROGATE CONSENT
KW - METAANALYSIS
KW - THERAPY
KW - UPDATE
KW - CARE
U2 - 10.1016/j.jstrokecerebrovasdis.2019.104447
DO - 10.1016/j.jstrokecerebrovasdis.2019.104447
M3 - Article
C2 - 31624035
SN - 1052-3057
VL - 28
SP - 1
EP - 9
JO - Journal of Stroke & Cerebrovascular Diseases
JF - Journal of Stroke & Cerebrovascular Diseases
IS - 12
M1 - 104447
ER -